1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
SenzaGen achieves 13% revenue growth in second quarter thanks to recovery at VitroScreen
SenzaGen reports a 13% increase in revenue in the second quarter to SEK 15.3 million, driven by a recovery at subsidiary VitroScreen and two large orders. The operating loss narrowed, earnings per share improved compared with the previous year, and operating cash flow was positive. The company maintained a stable gross margin, cited effective cost management, and expects EU regulations reducing animal testing to support long-term demand for its test solutions. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 1,38 M | 13,78 % |
| Beneficio bruto | 914,91 mil | 18,09 % |
| Beneficio neto | -200,15 mil | 58,00 % |
| EBITDA | -149,61 mil | 57,72 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 14,39 M € |
Número de acciones | 32,51 M |
Máximo/mínimo de 52 semanas | 0,61 € - 0,41 € |
| Dividendos | No |
Beta | 0,58 |
Ratio P/E | -14,31 |
Ratio PEG | -0,30 |
Ratio P/B | 1,81 |
Ratio P/S | 2,66 |
Perfil de la empresa
| Nombre | SENZAGEN AB |
| CEO | Peter Nahlstedt |
| Empleados | 34 |
